Compare Toronto-Dominion Bank (TD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs 10X Genomics Inc — how do they compare? Toronto-Dominion Bank trades at $123.3 (market cap $200.48B), while 10X Genomics Inc trades at $57.12 (market cap $7.61B). The key difference: Toronto-Dominion Bank is far larger — about 26.3× 10X Genomics Inc's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TD | TXG | |
|---|---|---|
Market Cap | $200.48B | $7.61B |
Sector | Financials | Health |
52-Week High | $124.80 | $58.57 |
52-Week Low | $72.85 | $11.34 |
Dividend Yield | 2.63% | — |
Enterprise Value | — | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD stock trades at $123.01, up 1.59% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong 2025 results with $61.28B revenue and $20.54B net income, though cash flow from operations was negative. Analyst consensus is positive with 9 buy ratings and no sell recommendations. Recent news highlights TD Auto Finance's industry recognition and AI-driven operational efficiencies.
The outlook is favorable given earnings momentum and dividend stability, but risks include volatile operating cash flows and high debt levels. Valuation metrics like P/E of 19.88 and P/B of 2.48 suggest reasonable pricing relative to peers, supporting a cautiously optimistic view for long-term investors.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
